Prospective Pathology Foundation Models

ConditionPancancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorNanfang Hospital, Southern Medical University

About this trial

Histopathology remains the gold standard for disease diagnosis, yet faces challenges including pathologist shortages and diagnostic model limitations. This underscores the critical need to develop deep learning-based pathology foundation models integrating prospective imaging and clinical data. Such models would enhance diagnostic accuracy and efficiency, enabling tumor grading, histo-molecular classification, and intelligent chemotherapy guidance - ultimately optimizing clinical workflows. However, a critical gap remains: the absence of prospectively validated, pan-disease pathology foundation models. Developing clinically validated models is therefore imperative.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Aged 18-75 years old.

Patients with complete pathological slides and clinical information.

Disqualifiers

None

Trial population

Inclusion criteria comprised patients aged 18-75 years with definitive pathological diagnoses. All cases were prospectively collected from Nanfang Hospital, Southern Medical University (NFHSMU) .

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

2,000 Participants
are grouped into 3 trial groups
Group A: QFSH external validation dataset
Group B: Prospective validation datasets
Group C: Randomized controlled trial

Trial outcomes

Primary outcomes

1

Area under ROC curve (AUC)

Area under the curve

Time frame
Diagnostic evaluation will be performed within 1 week when the WSIs are obtained

Secondary outcomes

1

Specificity

The true negative rate (TNR) of the diagnostic platform, which is the ratio between the number of negative individuals correctly categorized by platform and the total number of actual negative individuals (%).

Time frame
Diagnostic evaluation will be performed within 1 week when the WSIs are obtained
2

Sensitivity

The true positive rate (TPR) of the diagnostic platform, which is the ratio between the number of positive individuals correctly categorized by platform and the total number of actual positive individuals (%).

Time frame
Diagnostic evaluation will be performed within 1 week when the WSIs are obtained

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Nanfang Hospital, Southern Medical University

Lead sponsor

Qianfoshan Hospital

Collaborator

Zhejiang University

Collaborator

The First Affiliated Hospital of Zhengzhou University

Collaborator

First Affiliated Hospital of Shantou University Medical College

Collaborator

Zhujiang Hospital

Collaborator

Air Force Military Medical University, China

Collaborator